Mini-reviews
Vol. 2 No. 4 (2023)
Polycythemia vera and management of the thrombotic risk: an update
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 20 December 2023
2355
Views
355
Downloads
Authors
Polycythemia vera (PV) is a chronic Philadelphia-negative myeloproliferative neoplasm caused by JAK2 mutation and characterized predominantly by the overproduction of red blood cells. The current treatment strategies of PV are based on periodic phlebotomies aimed at preventing thrombotic events associated with increased hematocrit levels. Additional therapies to mitigate the thrombotic burden, which represents the most important predictor of reduced survival in PV patients, include cytoreductive therapies, low-dose aspirin, and systemic anticoagulation. This concise review summarizes the current knowledge on the management of the thrombotic risk in PV patients.
Downloads
Download data is not yet available.
Citations
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management. Am J Hematol 2024;98:1465-87. DOI: https://doi.org/10.1002/ajh.27002
Tefferi A, Vannucchi AM, Barbui T. Polycythemia vera: historical oversights, diagnostic details, and therapeutic views. Leukemia 2021;35:3339-351. DOI: https://doi.org/10.1038/s41375-021-01401-3
Guglielmelli P, Vannucchi AM. Current management strategies for polycythemia vera and essential thrombocythemia. Blood Rev 2020;42:100714. DOI: https://doi.org/10.1016/j.blre.2020.100714
Grunwald MR, Stein BL, Boccia RV, et al. Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. Clin Lymphoma Myeloma Leuk. 2018;18:788-95. DOI: https://doi.org/10.1016/j.clml.2018.08.009
Szuber N, Mudireddy M, Nicolosi M, et al. 3023 Mayo Clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc. 2019;94:599-610. DOI: https://doi.org/10.1016/j.mayocp.2018.08.022
Carobbio A, Ferrari A, Masciulli A, Ghirardi A, Barosi G, Barbui T. Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv 2019;3:1729-37. DOI: https://doi.org/10.1182/bloodadvances.2019000211
Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. Am J Hematol 2017;92:1131-6. DOI: https://doi.org/10.1002/ajh.24851
Landolfi R, Marchioli R, Kutti J, et al.; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24. DOI: https://doi.org/10.1056/NEJMoa035572
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224–32. DOI: https://doi.org/10.1200/JCO.2005.07.062
Mainoli B, Duarte GS, Costa J, Ferreira J, Caldeira D. Once- versus Twice-Daily Aspirin in Patients at High Risk of Thrombotic Events: Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs 2021;21:63-71. DOI: https://doi.org/10.1007/s40256-020-00409-x
How to Cite
1.
Franchini M. Polycythemia vera and management of the thrombotic risk: an update. Bleeding Thromb Vascul Biol [Internet]. 2023 Dec. 20 [cited 2026 Jan. 20];2(4). Available from: https://www.btvb.org/btvb/article/view/102
Copyright (c) 2023 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Similar Articles
- Maria J. Fernandez Turizo, Rushad Patell, Jeffrey I. Zwicker, Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- CO06 | Recurrences of catheter associated upper extremity deep vein thrombosis in cancer: a two year prospective study with enoxaparin , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Bianca Clerici, Mariangela Scavone, Gian Marco Podda, Recent advances in classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Niccolò Bitto, Vincenzo La Mura, Anna Ludovica Fracanzani, Armando Tripodi, Is non-alcoholic fatty liver disease a prothrombotic risk factor? , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- CS01 | Elucidating the evil relationship of metabolic dysfunction–associated fatty liver disease with cardiovascular comorbidities: the complex interplay among hypercoagulability, inflammation and liver fibrosis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Gualtiero Palareti, Paolo Prandoni, Cristina Legnani, Emilia Antonucci, Serena Zorzi, Alberto Tosetto, Lorenza Bertù, Sophie Testa, Vittorio Pengo, Walter Ageno, Ida Martinelli, Benilde Cosmi, Eugenio Bucherini, Daniela Poli, Rationale and design of a study on D-dimer use to stratify patients after a first unprovoked venous thromboembolism for their risk of recurrence: extended low-dose Apixaban given only to patients with positive D-dimer results , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 1 (2022)
- CO05 | Long-term management of upper extremity catheter-related thrombosis in female patients with cancer: a retrospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Matteo Guarascio, Gerardo Nicola Pititto, Alessia Abenante, Marco Paolo Donadini, Distal deep vein thrombosis: is there a way out of this dark forest? , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. s1 (2025)
- Mosaad Almegren, Clinical and radiological characteristics of cerebral vein thrombosis: a retrospective study , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
You may also start an advanced similarity search for this article.
Most read articles by the same author(s)
- Massimo Franchini, Daniele Focosi, The changing landscape of treatment for acquired hemophilia A , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
